Sean Gaine

Sean Gaine

Auto-generated profile, based on publicly available information

Sean Gaine

National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital Dublin Ireland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2009 in European Heart Journal
Verified
Journal Article
Open access
PDF file
NGNazzareno Galiè
Nazzareno Galiè
MHMarius Hoeper
Marius Hoeper
MHMarc Humbert
Marc Humbert
Adam TorbickiAdam Torbicki
Adam Torbicki
JVJean-Luc Vachiery
Jean-Luc Vachiery
JZJose Luis Zamorano
Jose Luis Zamorano
Guidelines and Expert Consensus Documents summarize and evaluate all currently available evidence on a particular issue with the aim to assist physicians in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk/benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously.

1 June 2009 in JACC
Verified
Journal Article
Closed access
GSGérald Simonneau
Gérald Simonneau
IRIvan M. Robbins
Ivan M. Robbins
MBMaurice Beghetti
Maurice Beghetti
RCRichard N. Channick
Richard N. Channick
MDMarion Delcroix
Marion Delcroix
RSRogério Souza
Rogério Souza

12 September 2009 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
NGN. Galiè
N. Galiè
MHMarius Hoeper
Marius Hoeper
MHM. Humbert
M. Humbert
Adam TorbickiAdam Torbicki
Adam Torbicki
JVJ-L. Vachiery
J-L. Vachiery
GSG. Simonneau
G. Simonneau
Guidelines and Expert Consensus Documents summarise and evaluate all currently available evidence on a particular issue with the aim to assist physicians in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk/benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously.

24 December 2015 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
OSOlivier Sitbon
Olivier Sitbon
RCRichard Channick
Richard Channick
KCKelly M. Chin
Kelly M. Chin
AFAline Frey
Aline Frey
SGSean Gaine
Sean Gaine
VMVallerie V. McLaughlin
Vallerie V. McLaughlin
In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension.

1 November 2011 in Circulation
Verified
Journal Article
Closed access
PDF file
JPJoanna Pepke-Zaba
Joanna Pepke-Zaba
MDMarion Delcroix
Marion Delcroix
ILIrene Lang
Irene Lang
EMEckhard Mayer
Eckhard Mayer
PJPavel Jansa
Pavel Jansa
GSGérald Simonneau
Gérald Simonneau
Background—: Chronic thromboembolic pulmonary hypertension (CTEPH) is often a sequel of venous thromboembolism with fatal natural history; however, many cases can be cured by pulmonary endarterectomy. The clinical characteristics and current management of patients enrolled in an international CTEPH registry was investigated. Methods and Results—: The international registry included 679 newly diagnosed (≤6 months) consecutive patients with CTEPH, from February 2007 until January 2009. Diagnosis was confirmed by right heart catheterization, ventilation-perfusion lung scintigraphy, computerized tomography, and/or pulmonary angiography. At diagnosis, a median of 14.1 months had passed since first symptoms; 427 patients (62.9%) were considered operable, 247 (36.4%) nonoperable, and 5 (0.7%) had no operability data; 386 patients (56.8%, ranging from 12.0%– 60.9% across countries) underwent surgery. Operable patients did not differ from nonoperable patients relative to symptoms, New York Heart Association class, and hemodynamics. A history of acute pulmonary embolism was reported for 74.8% of patients (77.5% operable, 70.0% nonoperable). Associated conditions included thrombophilic disorder in 31.9% (37.1% operable, 23.5% nonoperable) and splenectomy in 3.4% of patients (1.9% operable, 5.7% nonoperable). At the time of CTEPH diagnosis, 37.7% of patients initiated at least 1 pulmonary arterial hypertension–targeted therapy (28.3% operable, 53.8% nonoperable). Pulmonary endarterectomy was performed with a 4.7% documented mortality rate. Conclusions—: Despite similarities in clinical presentation, operable and nonoperable CTEPH patients may have distinct associated medical conditions. Operability rates vary considerably across countries, and a substantial number of patients (operable and nonoperable) receive off-label pulmonary arterial hypertension–targeted treatments.

1 June 2004 in JACC
Verified
Journal Article
Closed access
RBRobyn J Barst
Robyn J Barst
MMMichael McGoon
Michael McGoon
Adam TorbickiAdam Torbicki
Adam Torbicki
OSOlivier Sitbon
Olivier Sitbon
MKMichael J Krowka
Michael J Krowka
SGSean Gaine
Sean Gaine